Medical device affairs outsourcing market seen reaching $8.1 billion by 2031

A new market report projects the global medical device affairs outsourcing market will grow to $8.1 billion by 2031, up from $4.6 billion in 2021. The forecast points to rising regulatory complexity, cost pressure and more clinical and R&D activity as key reasons manufacturers are outsourcing more work.

Why it matters: - Medical device companies are outsourcing more regulatory, quality and clinical work as global compliance demands grow more complex. - The shift could lower costs, speed product launches and help smaller manufacturers access specialized expertise they may not be able to hire in-house. - The market’s growth reflects a broader push to bring new medical technologies to patients faster across multiple jurisdictions.

What happened: - Allied Market Research projected the global medical device affairs outsourcing market will reach $8.1 billion by 2031. - The report estimates a 6% compound annual growth rate from 2022 to 2031. - The market was valued at $4.6 billion in 2021. - The report was published June 9, 2026. - A sample PDF report is available through the company’s sample request page. - The full report is available through the report purchase page.

The details: - Rising regulatory complexity is the main growth driver identified in the report. - Medical device manufacturers must comply with rules and standards from agencies including the U.S. Food and Drug Administration and the European Medicines Agency. - Outsourcing lets manufacturers tap specialized expertise without building large in-house teams. - Small and medium-sized enterprises are a key customer group because they may lack the resources to manage regulatory demands alone. - Cost pressure is also pushing device makers toward outsourcing. - Regulatory affairs, quality assurance and clinical trial management are among the functions being outsourced. - The report says outsourcing can free resources for research and development and product innovation. - The report links market growth to more medical devices entering the market. - Demand for medical technology in emerging economies is also supporting expansion. - Companies launching products globally need country-by-country guidance to stay compliant and avoid delays.

Between the lines: - The forecast suggests outsourcing is moving from a support function to a core strategy for medical device commercialization. - The market opportunity is strongest where companies face the most fragmented rules and the highest cost of maintaining internal regulatory teams. - The report’s logic points to continued demand for firms that can manage multi-country compliance and clinical work at scale.

What’s next: - More medical device makers are likely to look for outside partners as R&D activity and clinical study volumes increase. - Outsourcing firms positioned across regulatory, quality and clinical services may benefit as manufacturers seek faster global market access. - The report expects the market to continue expanding through 2031 as regulatory and operational complexity rise.